

members. In accordance with OMB Final Guidance published in the **Federal Register** on October 5, 2011 and revised on August 13, 2014, federally registered lobbyists may not serve on the Committee in an individual capacity to provide their own individual best judgment and expertise, such as RGEs members. This ban does not apply to lobbyists appointed to provide the Committee with the views of a particular group, organization, or association, such as Representative members.

Nominations

Nominations for membership on the Committee will be accepted until Thursday, February 9, 2023. There are two parts to submitting a nomination. First, complete the information requested via this electronic form <https://forms.gle/iuBc67bMYjo1xB5V6>. Next, email your CV or resume and a letter of endorsement from your organization or organization's leadership to fscac@gsa.gov with the subject line: FSCAC NOMINATION—[Nominee Name].

Federal agencies may nominate qualified federal employees for Federal membership.

Non-Federal nominees must meet the following criteria in accordance with the FedRAMP Authorization Act of 2022:

- Individuals representing an independent assessment organization; or
- Representatives from unique businesses that primarily provide cloud computing services or products, including at least 2 representatives from a small business concern (as defined by section 3(a) of the Small Business Act (15 U.S.C. 632(a))).

Brian Conrad,

FedRAMP Director (Acting)/Cybersecurity Program Manager, Federal Risk and Authorization Management Program, General Services Administration.

[FR Doc. 2023–01481 Filed 1–24–23; 8:45 am]

BILLING CODE 6820–34–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—DD23–001, Birth Defects Study To Evaluate Pregnancy Exposures (BD–STEPS); Amended Notice of Closed Meeting

Notice is hereby given of a change in the meeting of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—DD23–001, Birth Defects Study To Evaluate Pregnancy exposures (BD–STEPS); March 28–29, 2023, 10 a.m.–5 p.m., EDT, Teleconference, in the original FRN. The meeting was published in the **Federal Register** on December 23, 2023, Volume 87, Number 246, page 78968.

The meeting is being amended to change the meeting date and time and should read as follows:

Date: March 29, 2023.

Time: 10 a.m.–6 p.m., EDT.

The meeting is closed to the public.

FOR FURTHER INFORMATION CONTACT:

Catherine Barrett, Ph.D., Scientific Review Officer, National Center for Chronic Disease Prevention and Health Promotion, CDC, 4770 Buford Highway, Mailstop S107–3, Atlanta, Georgia 30341–3717; Telephone: (404) 718–7664; Email: CBarrett@cdc.gov.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2023–01435 Filed 1–24–23; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Closed Meeting

Pursuant to section 1009(d) of 5 U.S.C. 10, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the

provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to Public Law 117–286. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—RFA–OH–23–002, Occupational Safety and Health Surveillance, Collaboration, Education, and Translation Review.

Date: March 22, 2023.

Time: 1 p.m.–3 p.m. EDT.

Place: Teleconference.

Agenda: To review and evaluate grant applications.

For Further Information Contact: Dan Hartley, Ph.D., Scientific Review Officer, Office of Extramural Programs, National Institute for Occupational Safety and Health, CDC, 1095 Willowdale Road, Morgantown, West Virginia 26506; Telephone: (304) 285–5812; Email: DHartleycdc.gov.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2023–01434 Filed 1–24–23; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2022–N–0198]

Mark Moffett; Denial of Hearing; Final Debarment Order

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.